Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 305 Thousand USD | 254.82% |
| 2021 | -197 Thousand USD | -113.36% |
| 2020 | 1.47 Million USD | -47.77% |
| 2019 | 2.82 Million USD | 8.71% |
| 2018 | 2.59 Million USD | 5.27% |
| 2017 | 2.46 Million USD | 550.82% |
| 2016 | -547 Thousand USD | 77.81% |
| 2015 | -2.46 Million USD | -11.49% |
| 2014 | -2.21 Million USD | 36.5% |
| 2013 | -3.48 Million USD | -55.45% |
| 2012 | -2.24 Million USD | 58.71% |
| 2011 | -5.42 Million USD | -47.78% |
| 2010 | -3.67 Million USD | -67.99% |
| 2009 | -2.18 Million USD | -472.47% |
| 2008 | -381.73 Thousand USD | 35.35% |
| 2007 | -590.43 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 305 Thousand USD | 0.0% |
| 2023 Q1 | 305 Thousand USD | 0.0% |
| 2022 FY | 305 Thousand USD | 254.82% |
| 2022 Q3 | 176 Thousand USD | 291.11% |
| 2022 Q4 | 305 Thousand USD | 73.3% |
| 2022 Q2 | 45 Thousand USD | 115.1% |
| 2022 Q1 | -298 Thousand USD | -51.27% |
| 2021 Q1 | -400 Thousand USD | -127.14% |
| 2021 FY | -197 Thousand USD | -113.36% |
| 2021 Q2 | -699 Thousand USD | -74.75% |
| 2021 Q3 | -555 Thousand USD | 20.6% |
| 2021 Q4 | -197 Thousand USD | 64.5% |
| 2020 Q3 | 2.13 Million USD | -17.73% |
| 2020 FY | 1.47 Million USD | -47.77% |
| 2020 Q1 | 2.48 Million USD | -11.94% |
| 2020 Q2 | 2.6 Million USD | 4.63% |
| 2020 Q4 | 1.47 Million USD | -31.09% |
| 2019 Q2 | 2.67 Million USD | 5.52% |
| 2019 Q4 | 2.82 Million USD | -0.18% |
| 2019 Q3 | 2.82 Million USD | 5.72% |
| 2019 Q1 | 2.53 Million USD | -2.39% |
| 2019 FY | 2.82 Million USD | 8.71% |
| 2018 Q2 | 2.53 Million USD | 1.12% |
| 2018 FY | 2.59 Million USD | 5.27% |
| 2018 Q4 | 2.59 Million USD | -3.99% |
| 2018 Q3 | 2.7 Million USD | 6.62% |
| 2018 Q1 | 2.5 Million USD | 1.7% |
| 2017 Q4 | 2.46 Million USD | 0.16% |
| 2017 Q3 | 2.46 Million USD | 41133.33% |
| 2017 Q2 | -6000.00 USD | 81.82% |
| 2017 FY | 2.46 Million USD | 550.82% |
| 2017 Q1 | -33 Thousand USD | 93.97% |
| 2016 Q3 | -330 Thousand USD | 64.36% |
| 2016 Q1 | -1.55 Million USD | 36.8% |
| 2016 FY | -547 Thousand USD | 77.81% |
| 2016 Q2 | -926 Thousand USD | 40.56% |
| 2016 Q4 | -547 Thousand USD | -65.76% |
| 2015 Q2 | -16 Thousand USD | 98.77% |
| 2015 Q1 | -1.29 Million USD | 41.29% |
| 2015 FY | -2.46 Million USD | -11.49% |
| 2015 Q4 | -2.46 Million USD | -117.18% |
| 2015 Q3 | -1.13 Million USD | -6993.75% |
| 2014 Q1 | -2.47 Million USD | 29.04% |
| 2014 Q3 | -3.45 Million USD | 26.29% |
| 2014 Q4 | -2.21 Million USD | 35.99% |
| 2014 Q2 | -4.68 Million USD | -89.64% |
| 2014 FY | -2.21 Million USD | 36.5% |
| 2013 FY | -3.48 Million USD | -55.45% |
| 2013 Q3 | -4.76 Million USD | -241.22% |
| 2013 Q2 | -1.39 Million USD | 43.01% |
| 2013 Q1 | -2.44 Million USD | -9.29% |
| 2013 Q4 | -3.48 Million USD | 26.85% |
| 2012 Q3 | -2.44 Million USD | 36.39% |
| 2012 Q1 | -4.77 Million USD | 11.91% |
| 2012 FY | -2.24 Million USD | 58.71% |
| 2012 Q4 | -2.24 Million USD | 8.37% |
| 2012 Q2 | -3.84 Million USD | 19.57% |
| 2011 Q1 | -6.75 Million USD | -83.88% |
| 2011 Q2 | -7.91 Million USD | -17.23% |
| 2011 FY | -5.42 Million USD | -47.78% |
| 2011 Q4 | -5.42 Million USD | 18.47% |
| 2011 Q3 | -6.65 Million USD | 15.92% |
| 2010 FY | -3.67 Million USD | -67.99% |
| 2010 Q4 | -3.67 Million USD | 3.29% |
| 2010 Q1 | -2.64 Million USD | -20.87% |
| 2010 Q2 | -4.46 Million USD | -69.2% |
| 2010 Q3 | -3.79 Million USD | 15.06% |
| 2009 FY | -2.18 Million USD | -472.47% |
| 2009 Q2 | -1.99 Million USD | -258.62% |
| 2009 Q4 | -2.18 Million USD | 10.39% |
| 2009 Q3 | -2.43 Million USD | -22.22% |
| 2009 Q1 | -556.36 Thousand USD | -45.74% |
| 2008 FY | -381.73 Thousand USD | 35.35% |
| 2008 Q4 | -381.73 Thousand USD | 0.0% |
| 2007 FY | -590.43 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 23382.443% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 94.6% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.287% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 222.186% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 104.838% |
| Qrons Inc. | 351.42 Thousand USD | 13.211% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 50.993% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.298% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1594.512% |
| Skye Bioscience, Inc. | -5.72 Million USD | 105.331% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 98.065% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 92.594% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 24.101% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.842% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 86.397% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 67.105% |
| Mesoblast Limited | 55.85 Million USD | 99.454% |
| Marizyme, Inc. | 18.56 Million USD | 98.357% |
| Genus plc | 190.6 Million USD | 99.84% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 86.359% |
| Pharming Group N.V. | 109.8 Million USD | 99.722% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 64.545% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 74.874% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 55.147% |
| ContraFect Corporation | -6.02 Million USD | 105.061% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -126.532% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 73.603% |
| IMV Inc. | 7.67 Million USD | 96.024% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 94.456% |
| MultiCell Technologies, Inc. | 90.04 USD | -338638.339% |
| ONE Bio Corp. | 9.04 Million USD | 96.626% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 141.554% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 97.644% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 77.704% |
| Q BioMed Inc. | 4.06 Million USD | 92.488% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.002% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 69.734% |
| Biomind Labs Inc. | 711.4 Thousand USD | 57.127% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.496% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 84.745% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 97.618% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 15.209% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -118.163% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1435.209% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 86.149% |
| GB Sciences, Inc. | 1.74 Million USD | 82.545% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 265.952% |
| HST Global, Inc. | 96.79 Thousand USD | -215.105% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -47.902% |
| Halberd Corporation | 144.72 Thousand USD | -110.75% |
| Enzolytics Inc. | 981.65 Thousand USD | 68.93% |
| Agentix Corp. | 37.63 Thousand USD | -710.502% |
| Resverlogix Corp. | 6.45 Million USD | 95.272% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 145.313% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.015% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.649% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 95.687% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 88.74% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 103.45% |
| AVAX Technologies, Inc. | -5.9 Million USD | 105.167% |
| Zenith Capital Corp. | 10.06 Thousand USD | -2930.604% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.029% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -52.171% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 87.217% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -85.4% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1765.029% |
| Kadimastem Ltd | -253.1 Thousand USD | 220.505% |
| Helix BioMedix, Inc. | -2.57 Million USD | 111.868% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.496% |
| BioStem Technologies, Inc. | 4.47 Million USD | 93.18% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -51.55% |
| LadRx Corporation | -2.03 Million USD | 114.977% |
| Cell Source, Inc. | 9.23 Million USD | 96.696% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 51.981% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 51.981% |
| NovAccess Global Inc. | 2.17 Million USD | 85.999% |
| Affymax, Inc. | -5.59 Million USD | 105.449% |
| Itoco Inc. | 228.3 Thousand USD | -33.593% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -124.283% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 93.847% |
| Mobile Lads Corp. | 484.23 Thousand USD | 37.014% |
| CytoDyn Inc. | 20.26 Million USD | 98.495% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 47240.649% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 3390.773% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 96.042% |
| SYBLEU INC | 473.71 Thousand USD | 35.615% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 93.157% |
| International Stem Cell Corporation | 2.59 Million USD | 88.224% |
| Bioxytran, Inc. | 1.89 Million USD | 83.938% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -388.68% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 86.015% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 91.118% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 96.434% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 60.523% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 124.4% |
| Neutra Corp. | 52.18 Thousand USD | -484.437% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 112.254% |
| PureTech Health plc | -167.19 Million USD | 100.182% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 224.537% |
| IXICO plc | -4.44 Million USD | 106.862% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 97.693% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.444% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Cellectis S.A. | -43.81 Million USD | 100.696% |